GlassScriptPhysician profile
Naresh K Parikh
NPI 1467409755
$5,092.95
in general payments reported to CMS, 2019-2025
34 companies · $707 in 2025
The $707 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $85.83 · 2021: $609 · 2022: $861 · 2023: $1,611 · 2024: $922 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,240.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $698.71 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $576.15 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Abbott Laboratories | $437.22 | 2021-2024 | Freestyle Libre 2, Mitraclip, Freestyle Libre 3 |
| Baxter Healthcare | $303.33 | 2023 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Pfizer INC. | $286.41 | 2022-2024 | |
| Amgen INC. | $259.91 | 2020-2025 | Krystexxa, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $229.02 | 2021-2022 | |
| Lilly USA, LLC | $221.87 | 2024-2025 | Zepbound, Mounjaro |
| Amarin Pharma, INC. | $172.42 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $169.27 | 2022-2024 | Camzyos |
| Lantheus Medical Imaging, INC. | $161.86 | 2022-2023 | Definity |
| Merck Sharp & Dohme LLC | $157.81 | 2023-2025 | Verquvo |
| Dexcom, INC. | $154.97 | 2022-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $124.98 | 2022 | |
| Rigel Pharmaceuticals, INC. | $124.85 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $120.96 | 2019 | |
| Ascensia Diabetes Care US INC. | $111.67 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.91 | 2019-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $106.99 | 2021-2023 | |
| Edwards Lifesciences Corporation | $91.79 | 2021-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic, INC. | $89.37 | 2025 | Interstim |
| Astellas Pharma US INC | $87.30 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.81 | 2024 | |
| Amryt Pharma Holdings LTD | $65.30 | 2022-2023 | Juxtapid |
| Exact Sciences Corporation | $44.00 | 2024 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $34.45 | 2023 | Injectafer |
| Abbvie INC. | $21.06 | 2023 | |
| Stemline Therapeutics INC. | $17.80 | 2025 | Elzonris |
| Esperion Therapeutics, INC. | $17.47 | 2025 | Nexletol |
| Vivaquant INC, Dba Rhythm Express | $11.29 | 2025 | Rhythm Express |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naresh Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.